Genocea Biosciences (GNCA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GNCA vs. NAVB, SCPS, EVLO, CMRA, GNCAQ, ARDS, STAB, EFTR, HSTO, and ONCSQShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Navidea Biopharmaceuticals (NAVB), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and OncoSec Medical (ONCSQ). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Navidea Biopharmaceuticals Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma eFFECTOR Therapeutics Histogen OncoSec Medical Navidea Biopharmaceuticals (NYSE:NAVB) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do institutionals and insiders have more ownership in NAVB or GNCA? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, NAVB or GNCA? Navidea Biopharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Does the media refer more to NAVB or GNCA? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Genocea Biosciences Neutral Which has stronger earnings and valuation, NAVB or GNCA? Navidea Biopharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K6.16-$15.18MN/AN/AGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/A Is NAVB or GNCA more profitable? Navidea Biopharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Genocea Biosciences N/A -182.88%-62.76% SummaryNavidea Biopharmaceuticals beats Genocea Biosciences on 5 of the 7 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNCA vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$273.10M$5.71B$9.51BDividend YieldN/AN/A4.60%3.99%P/E Ratio0.00N/A28.0720.02Price / SalesN/A364.35459.47103.02Price / CashN/A22.4436.5558.97Price / BookN/A12.118.615.88Net Income-$33.20M-$106.40M$3.24B$258.50M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$20K$8.13K0.0010SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070ARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5KN/A0.0030Gap UpSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020Negative NewsEFTReFFECTOR Therapeutics0.073 of 5 stars$0.00-50.0%N/A-99.6%$1KN/A0.0010Upcoming EarningsHSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies NAVB Competitors SCPS Competitors EVLO Competitors CMRA Competitors GNCAQ Competitors ARDS Competitors STAB Competitors EFTR Competitors HSTO Competitors ONCSQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNCA Stock Alerts